Literature DB >> 15531343

Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization.

Ghislaine Ducos De Lahitte1, Salomon Y Cohen, Alain Gaudric.   

Abstract

PURPOSE: To analyze the results of photodynamic therapy (PDT) in bilateral acquired parafoveal telangiectasis.
DESIGN: Interventional cases report.
METHOD: Retrospective analysis of visual acuity measured with ETDRS charts and of fluorescein angiography findings for two women in whom the eye with lesser visual acuity was treated by PDT for bilateral acquired parafoveal telangiectasis without subretinal neovascularization.
RESULTS: Initial visual acuity of the treated eye was 20/63 in both patients and did not change significantly for 3 to 6 months after one session of PDT. Fluorescein angiography in both cases and optical coherence tomography in one case also appeared unchanged. No adverse effect has been observed.
CONCLUSIONS: Photodynamic therapy was not beneficial for the outcome of these patients with bilateral acquired telangiectasis, because it improved neither their visual acuity nor their macular edema.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531343     DOI: 10.1016/j.ajo.2004.06.010

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

1.  Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm.

Authors:  Gökhan Demir; Özgür Artunay; Mehmet Emin Sucu; Ali Demircan; Dilek Yaşa; Cengiz Alagöz; Mevlüt Celal Öcal
Journal:  Lasers Med Sci       Date:  2018-05-26       Impact factor: 3.161

2.  Long-term course in type 2 idiopathic macular telangiectasia.

Authors:  Tobias Meyer-ter-Vehn; Sina Herzog; Marc Schargus; Winfried Göbel; Rainer Guthoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-25       Impact factor: 3.117

3.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 4.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

5.  Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study.

Authors:  J Fernando Arevalo; Juan G Sanchez; Reinaldo A Garcia; Lihteh Wu; Maria H Berrocal; Francisco J Rodriguez; Alvaro Rodríguez; Liliana Andrea Novoa; Rafael Garcia-Amaris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-10       Impact factor: 3.117

6.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

7.  Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia.

Authors:  Tyler A Berger; Matthew W Manry; Lucas B Lindsell; James M Osher; Daniel M Miller; Robert E Foster; Christopher D Riemann; Michael R Petersen; Robert A Sisk
Journal:  Clin Ophthalmol       Date:  2021-03-15

8.  Macular telangiectasia type 2 accompanied by solitary retinal astrocytic hamartoma (case report).

Authors:  Martin Pencak; Jan Krasny; Miroslav Veith; Magdalena Vokrojova
Journal:  BMC Ophthalmol       Date:  2016-11-11       Impact factor: 2.209

9.  Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia.

Authors:  Alexandros Rouvas; Panagiotis Malamos; Maria Douvali; Amalia Ntouraki; Nikos N Markomichelakis
Journal:  Clin Ophthalmol       Date:  2013-07-05

Review 10.  Widening use of dexamethasone implant for the treatment of macular edema.

Authors:  Vincenza Bonfiglio; Michele Reibaldi; Matteo Fallico; Andrea Russo; Alessandra Pizzo; Stefano Fichera; Carlo Rapisarda; Iacopo Macchi; Teresio Avitabile; Antonio Longo
Journal:  Drug Des Devel Ther       Date:  2017-08-16       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.